Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Excretion Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

NCT01663389
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 1000 mg containing radioactive 14C-GSK1322322, GSK1322322 1200 mg containing radioactive 14C-GSK1322322
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 19, 2026, 2:53 AM EDT
Completed No phase listed Observational

Evaluation of Nocturnal Enuresis and Barriers to Treatment Among Pediatric Patients With Sickle Cell Disease

NCT01959958
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Questionnaire/Interview
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects

NCT05554926
View directory record Official record
Conditions
Marijuana Abuse
Interventions
AEF0117
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092

NCT05074134
View directory record Official record
Conditions
Healthy
Interventions
[14C]-TNP-2092
Drug
Lead sponsor
TenNor Therapeutics Limited
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.

NCT03202693
View directory record Official record
Conditions
Tuberculosis
Interventions
PA-824
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers

NCT00722306
View directory record Official record
Conditions
Insomnia
Interventions
PD 0200390
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 4, 2011 · Synced Oct 19, 2026, 2:53 AM EDT
Suspended Not applicable Interventional

A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination

NCT06168942
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation, Stroke, Systemic Embolism
Interventions
Experimental: Laminar Left Atrial Appendage Closure System, Active Comparator: WATCHMAN / Amulet
Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Not applicable Interventional Results available

Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease

NCT01684722
View directory record Official record
Conditions
Diabetes
Interventions
Vitamin D, Omega-3 fatty acids (fish oil), Vitamin D placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older
Enrollment
1,312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects

NCT01299285
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY3009104
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants

NCT05873764
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
200 mg RV521/78 µCi [ 14C]-RV521.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120

NCT02489513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-AG-120
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of [14C]-LY3866288 in Healthy Participants

NCT06644378
View directory record Official record
Conditions
Healthy
Interventions
[14C]-LY3866288, LY3866288
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion

NCT01059474
View directory record Official record
Conditions
Toxicity
Interventions
transdermal DMPS
Drug
Lead sponsor
Banner Health
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RE104 Radiolabeled Mass Balance (hAME) Study

NCT07146191
View directory record Official record
Conditions
Healthy Participant Study
Interventions
2-[14C]-RE104 for Injection
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

NCT01605461
View directory record Official record
Conditions
Healthy
Interventions
BI 207127 NA
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants

NCT06745271
View directory record Official record
Conditions
Healthy Participants
Interventions
[14C]-tebapivat, [13C2,15N3]-tebapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 19, 2026, 2:53 AM EDT
Withdrawn Not applicable Interventional

Viberect Penile Vibratory Stimulation to Enhance Recovery of Erectile Function and Urinary Continence Post-Prostatectomy

NCT01718704
View directory record Official record
Conditions
Erectile Dysfunction Following Radical Prostatectomy, Urinary Incontinence of Non-organic Origin
Interventions
Viberect device
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 70 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Physiological Study of Human Cholesterol Metabolism and Excretion

NCT01603758
View directory record Official record
Conditions
Coronary Heart Disease, Cardiovascular Disease, Dyslipidemia, Disorder of Cholesterol Metabolism
Interventions
Ezetimibe
Drug
Lead sponsor
Richard E. Ostlund Jr., MD
Other
Eligibility
18 Years to 80 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics

NCT05628961
View directory record Official record
Conditions
Toxicity;Chemical
Interventions
HOPO 14-1
Drug
Lead sponsor
SRI International
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Plymouth, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects

NCT03163173
View directory record Official record
Conditions
Healthy Volunteers, Healthy
Interventions
GC4419
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 19, 2026, 2:53 AM EDT
Active, not recruiting No phase listed Observational

A Prospective Study of the Four Food Elimination Diet for Treatment of Eosinophilic Esophagitis

NCT05176262
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Year to 18 Years
Enrollment
64 participants
Timeline
2011 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women

NCT00532077
View directory record Official record
Conditions
Osteoporosis
Interventions
rhPTH(1-34), SB-751689 100 mg, SB-751689 400 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
San Diego, California • Daytona Beach, Florida • Port Orange, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 19, 2026, 2:53 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)

NCT02044601
View directory record Official record
Conditions
Lung Cancer
Interventions
Onartuzumab, Erlotinib, Paclitaxel, Carboplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 19, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

NCT05847439
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]BMS-986419
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 19, 2026, 2:53 AM EDT